140 related articles for article (PubMed ID: 29323859)
1. Calculated decisions: MASCC Risk Index for febrile neutropenia.
Taylor J
Emerg Med Pract; 2018 Jan; 20(Suppl 1):3-4. PubMed ID: 29323859
[No Abstract] [Full Text] [Related]
2. Calculated decisions: Absolute neutrophil count.
Patel S
Emerg Med Pract; 2018 Jan; 20(Suppl 1):1-2. PubMed ID: 29323858
[No Abstract] [Full Text] [Related]
3. Application of the MASCC and CISNE Risk-Stratification Scores to Identify Low-Risk Febrile Neutropenic Patients in the Emergency Department.
Coyne CJ; Le V; Brennan JJ; Castillo EM; Shatsky RA; Ferran K; Brodine S; Vilke GM
Ann Emerg Med; 2017 Jun; 69(6):755-764. PubMed ID: 28041827
[TBL] [Abstract][Full Text] [Related]
4. Accuracy of the Multinational Association of Supportive Care in Cancer (MASCC) and Clinical Index of Stable Febrile Neutropenia (CISNE) scores for predicting serious complications in adult patients with febrile neutropenia: A systematic review and meta-analysis.
Zheng B; Toarta C; Cheng W; Taljaard M; Reaume N; Perry JJ
Crit Rev Oncol Hematol; 2020 May; 149():102922. PubMed ID: 32244162
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the MASCC and CISNE scores for identifying low-risk neutropenic fever patients: analysis of data from three emergency departments of cancer centers in three continents.
Ahn S; Rice TW; Yeung SJ; Cooksley T
Support Care Cancer; 2018 May; 26(5):1465-1470. PubMed ID: 29168032
[TBL] [Abstract][Full Text] [Related]
6. CISNE versus MASCC: Identifying low risk febrile neutropenic patients.
Mohindra R; Mathew R; Yadav S; Aggarwal P
Am J Emerg Med; 2020 Nov; 38(11):2259-2263. PubMed ID: 31864874
[TBL] [Abstract][Full Text] [Related]
7. Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score.
Uys A; Rapoport BL; Anderson R
Support Care Cancer; 2004 Aug; 12(8):555-60. PubMed ID: 15197637
[TBL] [Abstract][Full Text] [Related]
8. The MASCC Neutropenia, Infection and Myelosuppression Study Group evaluates recent new concepts for the use of granulocyte colony-stimulating factors for the prevention of febrile neutropenia.
Klastersky J; Raftopoulos H; Rapoport B
Support Care Cancer; 2013 Jun; 21(6):1793-5. PubMed ID: 23525960
[No Abstract] [Full Text] [Related]
9. C-reactive protein and the MASCC risk index identify high-risk patients with febrile neutropenia and hematologic neoplasms.
Combariza JF; Lombana M; Pino LE; Arango M
Support Care Cancer; 2015 Apr; 23(4):1009-13. PubMed ID: 25270848
[TBL] [Abstract][Full Text] [Related]
10. Common misconceptions in the prognostic evaluation of clinically stable patients with febrile neutropenia and solid tumors.
Carmona-Bayonas A; Jiménez-Fonseca P
Clin Transl Oncol; 2019 Aug; 21(8):1112-1114. PubMed ID: 30607791
[No Abstract] [Full Text] [Related]
11. Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice.
Innes H; Lim SL; Hall A; Chan SY; Bhalla N; Marshall E
Support Care Cancer; 2008 May; 16(5):485-91. PubMed ID: 17899215
[TBL] [Abstract][Full Text] [Related]
12. Potential reduction of hospital stay length with outpatient management of low-risk febrile neutropenia in a regional cancer center.
Nguyen M; Jacobson T; Torres J; Wann A
Cancer Rep (Hoboken); 2021 Jun; 4(3):e1345. PubMed ID: 33635593
[TBL] [Abstract][Full Text] [Related]
13. Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study.
Carmona-Bayonas A; Jiménez-Fonseca P; Virizuela Echaburu J; Antonio M; Font C; Biosca M; Ramchandani A; Martínez J; Hernando Cubero J; Espinosa J; Martínez de Castro E; Ghanem I; Beato C; Blasco A; Garrido M; Bonilla Y; Mondéjar R; Arcusa Lanza MÁ; Aragón Manrique I; Manzano A; Sevillano E; Castañón E; Cardona M; Gallardo Martín E; Pérez Armillas Q; Sánchez Lasheras F; Ayala de la Peña F
J Clin Oncol; 2015 Feb; 33(5):465-71. PubMed ID: 25559804
[TBL] [Abstract][Full Text] [Related]
14. Utility of the Multinational Association for Supportive Care in Cancer (MASCC) Risk Index Score as a Criterion for Nonadmission in Febrile Neutropenic Patients with Solid Tumors.
Bitar RA
Perm J; 2015; 19(3):37-47. PubMed ID: 26176568
[TBL] [Abstract][Full Text] [Related]
15. SEOM clinical practice guideline: management and prevention of febrile neutropenia in adults with solid tumors (2018).
Carmona-Bayonas A; Jimenez-Fonseca P; de Castro EM; Mata E; Biosca M; Custodio A; Espinosa J; Vázquez EG; Henao F; Ayala de la Peña F
Clin Transl Oncol; 2019 Jan; 21(1):75-86. PubMed ID: 30470991
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of Serum Procalcitonin Levels in Patients With Febrile Neutropenia Presenting to the Emergency Department.
Yadav S; Mathew R; Sahu AK; Jamshed N; Mohindra R; Aggarwal P; Batra A; Halder D; Brunda RL
J Emerg Med; 2021 May; 60(5):641-647. PubMed ID: 33518374
[TBL] [Abstract][Full Text] [Related]
17. Fifteen minute consultation: Fever in children being treated for cancer.
Morgan JE
Arch Dis Child Educ Pract Ed; 2019 Jun; 104(3):124-128. PubMed ID: 30104324
[TBL] [Abstract][Full Text] [Related]
18. Predictive Indicators to Identify High-Risk Paediatric Febrile Neutropenia in Paediatric Oncology Patients in a Middle-Income Country.
Green LL; Goussard P; van Zyl A; Kidd M; Kruger M
J Trop Pediatr; 2018 Oct; 64(5):395-402. PubMed ID: 29149345
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of monocytes and lymphocytes for short-term neutrophil changes in chemotherapy-induced severe neutropenia in solid tumors.
Zheng B; Huang Z; Huang Y; Hong L; Li J; Wu J
Support Care Cancer; 2020 Mar; 28(3):1289-1294. PubMed ID: 31240465
[TBL] [Abstract][Full Text] [Related]
20. Management of febrile neutropenia in malignancy using the MASCC score and other factors: Feasibility and safety in routine clinical practice.
Kumar P; Bajpai J; Shetty N; Medekar A; Kurkure PA; Ghadyalpatil N; Gupta S; Noronha V; Kanujia A; Parikh P; Banavali SD
Indian J Cancer; 2014; 51(4):491-5. PubMed ID: 26842174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]